| abstract |
The present disclosure provides combination therapies, compositions and kits comprising (a) a long-acting IL-15 receptor agonist and (b) one or more antibodies (mAbs) that target a tumor antigen, and related methods of making and using them, e.g. , a method of use in the treatment of a condition responsive to therapy effective to provide sustained immune activation and/or anti-tumor activity. |